Drug Profile
IPH 5201
Alternative Names: anti-huCD39 mAb; IPH-52; IPH5201Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator INSERM; Orega Biotech
- Developer AstraZeneca; Innate Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD39 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 23 Jun 2023 Phase-II clinical trials in Non-small cell lung cancer (Early-stage disease, First-line therapy, Adjuvant therapy, Neoadjuvant therapy) in France, USA (IV) (NCT05742607)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (Parenteral)